President Donald Trump on Thursday announced a deal that could significantly expand access for millions of Americans to hugely popular obesity drugs by reducing the price to as little as $150 a month.

The Trump administration’s agreements with drugmakers Novo Nordisk and Eli Lilly would save consumers and the government considerable money on Wegovy, Zepbound and two obesity pills that are expected to win regulatory approval in the coming months.

The lowest price, of $150 a month, will be available only for the lowest doses of the pill form of the drugs. When those drugs reach the market, Medicare and Medicaid will pay that price, as will Americans using their own money to buy the pills directly from manufacturers.

The deal also broadens coverage of the injectable drugs for people on Med

See Full Page